Domain Structure of Thrombomodulin
The domain structure of thrombomodulin is represented, where: EGF = regions containing sequence homologous to human epidermal growth factor, O-GLYCOS = region rich in O-glycosylation sites, MEM = membrane spanning region, CYTO = cytoplasmic domain containing a free cycteine.
Price $339.00/50 µg ($306.00/min. 5)
Size 50 µg Formulation 20 mM Tris, 150 mM NaCl, 0.05% PDOC, pH 7.4 Storage -80°C Purity >95% by SDS-PAGE Activity Determination Protein C activation assay Shelf Life (properly stored) 12 months
Thrombomodulin (TM) is an integral membrane glycoprotein expressed on the surface of endothelial cells. Its discovery by Esmon and Owen has focused attention on the importance of the protein C anticoagulant pathway (1,2). TM serves as a cofactor for protein C activation by forming a 1:1 stoichiometric complex with thrombin (Kd=10-10M), which accelerates the rate of protein C activation by 1000-fold relative to the rate with thrombin alone. In addition to facilitating protein C activation, the binding of thrombin to TM drastically alters the procoagulant activity of thrombin. When bound to TM, thrombin no longer clots fibrinogen, activates factor V, inactivates protein S or triggers platelet aggregation.
TM is a single chain protein composed of 5 distinct domains. The domain structure of TM is similar to the low density lipoprotein (LDL) receptor. A short cytoplasmic domain containing a free cysteine is located at the COOH-terminal end and is joined by a membrane spanning region to an O-glycosylation rich domain. The latter is followed by an epidermal growth factor (EGF) homology region and the NH2-terminal hydrophobic domain. The EGF homology region contains 6 EGF-like domains and contains the binding sites for both thrombin and protein C.
Thrombomodulin is isolated from rabbit lung by a modification (3) of the procedure described by Galvin et al. (4) and is supplied as an aqueous solution in 0.02 M Tris, 0.15 M NaCl, pH 7.4, containing 0.05 % polidocanol, and can be stored at -80°C for up to a year. Purity is determined by SDS-PAGE analysis and activity is determined using a chromogenic assay for protein C activation.
|Localization||Endothelial cell membrane, traces of degraded, yet functional, TM detected in human urine and plasma (7,8)|
|Mode of Action||Cofactor; enhances the proteolytic activation of protein C by thrombin|
|Molecular weight||74,000 (5)|
|Isoelectric point||2.5 (2)|
|Structure||Single chain, NH2-terminal hydrophobic domain, six EGF domains, one O-glycosylation rich domain, one transmembrane domain, COOH-terminal cytoplasmic domain|
|Post-translational modifications||β-hydroxyasparagine (0.5 mol/mol of protein) (6)|
- Esmon, C.T., et al., Proc. Natl. Acad. Sci. USA, 78, 2249 (1981).
- Esmon, N.L., Semin. Thromb. Hemostas., 13, 454 (1987).
- Haley, P.E., et al., J. Biol. Chem., 264, 16303 (1989).
- Galvin, J.B., et al., J. Biol. Chem., 262, 2199 (1987).
- Esmon, N.L., et al., J. Biol. Chem., 257, 859 (1982).
- Stenflo, J., et al., J. Biol. Chem., 263, 21 (1988).
- DeBault, L.E., et al., Lab Invest., 54, 172 (1986).
- Ishi, J., et al., J. Clin. Invest., 76, 2178 (1985).
- Zachary, J., et al., Ultrasound Med Biol. 2006 November ; 32(11): 1781–1791. (stanard in ELISA)
- Panteleev, M., et al., Biophysical Journal Volume 90 March 2006 1489–1500 (inhibition of clot growth)
This publication list is not all encompassing, and is only meant to provide limited examples of how Haematologic Technologies' products are used. We encourage you to search the literature for other examples pertinent to your experimentation, and to contact us with any technical questions.